March 12, 2020 / 11:23 AM / a month ago

BRIEF-Trevena Reports Fourth Quarter And Full Year 2019 Results

March 12 (Reuters) - Trevena Inc:

* TREVENA REPORTS FOURTH QUARTER AND FULL YEAR 2019 RESULTS

* Q4 LOSS PER SHARE $0.07

* UPDATED GUIDANCE ON EXTENDED CASH RUNWAY, FUNDING OPERATIONS INTO Q1 2021

* PDUFA DATE OF AUGUST 7, 2020 FOR IV OLICERIDINE; FDA CONSIDERS NDA RESUBMISSION COMPLETE

* INITIATED PROOF-OF-CONCEPT STUDIES FOR ACUTE MIGRAINE (TRV250) AND OPIOID USE DISORDER (TRV734)

* ANNOUNCES NIH COLLABORATION TO EVALUATE TRV045 FOR EPILEPSY Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below